Suppr超能文献

体外生成淀粉样纤维:一种研究AL淀粉样变性的工具。

Producing amyloid fibrils in vitro: A tool for studying AL amyloidosis.

作者信息

Sizova Daria V, Raiker Steve, Lakheram Deaneira, Rao Vishwanatha, Proffitt Andrew, Jmeian Yazen, Voegtli Walter, Batonick Melissa

机构信息

Alexion AstraZeneca Rare Disease, 100 College Street, New Haven, CT, 06510, USA.

出版信息

Biochem Biophys Rep. 2023 Feb 24;34:101442. doi: 10.1016/j.bbrep.2023.101442. eCollection 2023 Jul.

Abstract

Amyloid light-chain (AL) amyloidosis is the second most common form of systemic amyloidosis which is characterized by a high level of mortality and no effective treatment to remove fibril deposition. This disorder is caused by malfunctioning of B-cells resulting in production of abnormal protein fibrils composed of immunoglobulin light chain fragments that tend to deposit on various organs and tissues. AL amyloidosis is set apart from other forms of amyloidosis in that no specific sequences have been identified in the immunoglobulin light chains that are amyloid fibril formation causative and patient specific. This unusual feature hinders the therapeutic progress and requires either direct access to patient samples (which is not always possible) or a source of in vitro produced fibrils. While isolated reports of successful AL amyloid fibril formation from various patient-specific protein sequences can be found in literature, no systematic research on this topic was performed since 1999. In the present study we have developed a generalized approach to in vitro fibril production from various types of previously reported [[1], [2], [3]] amyloidogenic immunoglobulin light chains and their fragments. We describe the procedure from selection and generation of starting material, through finding of optimal assay conditions, to applying a panel of methods to confirm successful fibril formation. Procedure details are discussed in the light of the most recent findings and theories on amyloid fibril formation. The reported protocol produces high quality AL amyloid fibrils that can subsequently be used in the development of the much-needed amyloid-targeting diagnostic and therapeutic approaches.

摘要

淀粉样轻链(AL)淀粉样变性是系统性淀粉样变性的第二常见形式,其特点是死亡率高且没有有效方法去除纤维沉积。这种疾病是由B细胞功能异常引起的,导致产生由免疫球蛋白轻链片段组成的异常蛋白纤维,这些纤维倾向于沉积在各种器官和组织上。AL淀粉样变性与其他形式的淀粉样变性的不同之处在于,在导致淀粉样纤维形成且具有患者特异性的免疫球蛋白轻链中尚未鉴定出特定序列。这一不寻常的特征阻碍了治疗进展,需要直接获取患者样本(这并非总是可行)或体外产生的纤维来源。虽然在文献中可以找到关于从各种患者特异性蛋白序列成功形成AL淀粉样纤维的个别报道,但自1999年以来尚未对该主题进行系统研究。在本研究中,我们开发了一种通用方法,用于从各种先前报道的[[1], [2], [3]]淀粉样生成免疫球蛋白轻链及其片段体外生产纤维。我们描述了从起始材料的选择和生成,到找到最佳检测条件,再到应用一系列方法确认成功形成纤维的过程。根据关于淀粉样纤维形成的最新发现和理论讨论了操作细节。所报道的方案可产生高质量的AL淀粉样纤维,随后可用于开发急需的针对淀粉样蛋白的诊断和治疗方法。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a6a2/9982448/5dcbc092ffac/ga1.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验